
  
    
      
        Background_NNP
        The_DT promise_NN of_IN improved_VBN outcome_NN with_IN the_DT use_NN of_IN
        hematopoietic_JJ growth_NN factors_NNS in_IN the_DT treatment_NN of_IN acute_JJ
        myelogenous_JJ leukemia_NN (_( AML_NNP )_) has_VBZ yet_RB to_TO be_VB realized_VBN ._. In_IN
        several_JJ prospective_JJ trials_NNS ,_, patients_NNS were_VBD randomized_JJ to_TO
        either_CC a_DT hematopoietic_JJ growth_NN factor_NN or_CC a_DT placebo_NN after_IN
        induction_NN chemotherapy_NN in_IN an_DT attempt_NN to_TO accelerate_VB
        neutrophil_NN recovery_NN and_CC improve_VB outcome_NN ._. These_DT studies_NNS
        consistently_RB show_NN accelerated_VBD neutrophil_NN recovery_NN without_IN
        an_DT increase_NN in_IN leukemic_JJ relapse_NN in_IN patients_NNS treated_VBN with_IN
        either_DT granulocyte_NN colony_NN stimulating_VBG factor_NN (_( G-CSF_NNP )_) or_CC
        granulocyte-macrophage_JJ colony_NN stimulating_VBG factor_NN (_( GM-CSF_NNP )_) ._.
        [_NN 1_CD 2_CD 3_CD 4_CD ]_NN Unfortunately_RB these_DT studies_NNS have_VBP failed_VBN to_TO
        consistently_RB show_VB a_DT benefit_NN in_IN terms_NNS of_IN remission_NN and_CC
        survival_NN when_WRB administered_VBN in_IN such_JJ an_DT adjuvant_NN fashion_NN ._. [_NN 5_CD
        6_CD ]_NN
        The_DT hematopoietic_JJ growth_NN factors_NNS have_VBP also_RB been_VBN studied_VBN
        for_IN their_PRP$ therapeutic_JJ benefits_NNS when_WRB given_VBN before_IN
        chemotherapy_NN ._. Both_DT G-CSF_NNP and_CC GM-CSF_NNP recruit_VB quiescent_JJ
        leukemic_JJ blasts_NNS into_IN cell_NN cycle_NN thus_RB rendering_VBG them_PRP more_RBR
        susceptible_JJ to_TO the_DT S-_NNP phase_NN specific_JJ cytotoxicity_NN of_IN
        cytarabine_NN ._. [_NN 7_CD 8_CD 9_CD 10_CD 11_CD 12_CD 13_CD ]_NN Several_JJ studies_NNS suggest_VBP a_DT
        potential_JJ therapeutic_JJ benefit_NN from_IN administering_VBG
        hematopoietic_JJ growth_NN factors_NNS before_IN starting_VBG
        cytarabine-based_JJ chemotherapy_NN ._. [_NN 14_CD 15_CD 16_CD 17_CD 18_CD 19_CD ]_NN
        However_RB ,_, the_DT results_NNS of_IN larger_JJR randomized_JJ trials_NNS have_VBP been_VBN
        disappointing_JJ ._. [_NN 20_CD 21_CD 22_CD 23_CD ]_NN Not_RB only_RB have_VBP remission_NN and_CC
        survival_NN rates_NNS not_RB been_VBN increased_VBN but_CC the_DT direct_JJ effect_NN of_IN
        growth_NN factors_NNS on_IN the_DT untreated_JJ leukemia_NN has_VBZ led_VBN to_TO severe_JJ
        toxic_JJ reactions_NNS and_CC death_NN ._. [_NN 24_CD 25_CD 26_CD ]_NN
        Chemotherapy_NNP also_RB recruits_VBZ quiescent_JJ leukemic_JJ blasts_NNS
        into_IN cell_NN cycle_NN ._. Burke_NNP and_CC colleagues_NNS demonstrated_VBN in_IN an_DT 
        in_IN vitro_NN model_NN that_IN following_VBG an_DT
        initial_JJ cycle_NN of_IN chemotherapy_NN "_'' humoral_NN factors_NNS "_'' are_VBP
        generated_VBN which_WDT are_VBP capable_JJ of_IN recruiting_VBG quiescent_JJ
        leukemic_JJ blasts_NNS into_IN S-_NNP phase_NN ._. [_NN 27_CD ]_NN The_DT maximal_NN
        recruitment_NN occurred_VBD about_IN 4_CD to_TO 6_CD days_NNS after_IN chemotherapy_NN
        was_VBD administered_VBN ._. To_TO apply_VB these_DT observations_NNS clinically_RB ,_,
        patients_NNS were_VBD first_RB treated_VBN with_IN cytarabine_NN and_CC
        daunorubicin_NN ._. This_DT initial_JJ cycle_NN of_IN chemotherapy_NN was_VBD then_RB
        followed_VBN by_IN either_DT a_DT second_JJ course_NN of_IN cytarabine_NN on_IN day_NN 10_CD
        or_CC AMSA_NNP on_IN days_NNS 8_CD -_: 10_CD ._. This_DT "_'' timed_VBN sequential_NN therapy_NN "_''
        achieved_VBD a_DT complete_JJ remission_NN rate_NN of_IN 88_CD %_NN in_IN 
        de_IN novo_NN and_CC 70_CD %_NN in_IN secondary_JJ AML_NNP ._. [_NN
        28_CD ]_NN Timed_NNP sequential_NN therapy_NN has_VBZ been_VBN employed_VBN in_IN relapsed_JJ
        and_CC 
        de_IN novo_NN acute_JJ leukemia_NN and_CC achieves_VBZ
        complete_JJ remission_NN rates_NNS comparable_JJ to_TO those_DT achieved_VBN with_IN
        other_JJ salvage_NN chemotherapeutic_JJ regimens_NNS ._. [_NN 29_CD 30_CD ]_NN
        The_DT combination_NN of_IN timed_VBN sequential_NN chemotherapy_NN and_CC
        hematopoietic_JJ growth_NN factors_NNS allows_VBZ for_IN an_DT initial_JJ
        cytoreductive_JJ course_NN of_IN chemotherapy_NN before_IN starting_VBG growth_NN
        factors_NNS ._. The_DT growth_NN factor_NN could_MD then_RB work_VB with_IN the_DT other_JJ
        "_'' humoral_NN factors_NNS "_'' generated_VBN by_IN chemotherapy_NN to_TO maximize_VB
        recruitment_NN of_IN leukemic_JJ blasts_NNS into_IN cell_NN cycle_NN ._. Few_JJ studies_NNS
        have_VBP tested_VBN this_DT approach_NN ._. We_PRP report_VBP the_DT results_NNS of_IN a_DT
        clinical_JJ trial_NN assessing_VBG the_DT potential_JJ benefit_NN of_IN adding_VBG
        G-CSF_NNP to_TO a_DT proven_VBN timed_VBN sequential_NN chemotherapeutic_JJ
        regimen_NN ._.
      
      
        Materials_NNS and_CC Methods_NNP
        
          Patients_NNS
          All_DT patients_NNS had_VBD AML_NNP defined_VBD according_VBG to_TO the_DT standard_JJ
          French-_NNP American-_NNP British_JJ (_( FAB_NNP )_) cytologic_JJ and_CC cytochemical_JJ
          criteria_NNS [_NN 47_CD ]_NN ._. Patients_NNPS were_VBD considered_VBN to_TO have_VB
          good-risk_JJ cytogenetics_NNS if_IN their_PRP$ karyotype_NN revealed_VBD either_CC
          t_NN (_( 8_CD ;_: 21_CD )_) ,_, inv_NN (_( 16_CD )_) ,_, t_NN (_( 16_CD ;_: 16_CD )_) or_CC t_NN (_( 15_CD :_: 17_CD )_) ._. A_DT normal_JJ
          karyotype_NN defined_VBD intermediate-risk_JJ cytogenetics_NNS ._. All_DT
          other_JJ clonal_NN abnormalities_NNS were_VBD considered_VBN poor-risk_JJ ._.
          Patients_NNS were_VBD eligible_JJ for_IN this_DT protocol_NN if_IN their_PRP$
          leukemia_NN was_VBD :_: 1_LS )_) refractory_JJ to_TO previous_JJ induction_NN
          chemotherapy_NN ,_, 2_LS )_) in_IN first_JJ or_CC subsequent_JJ relapse_NN after_IN
          initial_JJ complete_JJ remission_NN following_VBG induction_NN
          chemotherapy_NN ,_, 3_LS )_) secondary_JJ to_TO transformation_NN from_IN an_DT
          antecedent_NN hematologic_JJ disorder_NN ,_, or_CC 4_LS )_) secondary_JJ to_TO
          previous_JJ exposure_NN to_TO cytotoxic_JJ agents_NNS ._. All_DT patients_NNS were_VBD
          over_IN 18_CD years_NNS of_IN age_NN ._. Only_RB patients_NNS with_IN a_DT performance_NN
          status_NN of_IN 2_CD or_CC less_JJR and_CC no_DT organ_NN failure_NN [_NN less_JJR than_IN grade_NN
          2_CD according_VBG to_TO the_DT World_NNP Health_NNP Organization_NNP (_( WHO_WP )_)
          grading_VBG system_NN ]_NN could_MD enter_VB the_DT study_NN ,_, except_IN if_IN organ_NN
          failure_NN was_VBD related_VBN to_TO the_DT leukemia_NN itself_PRP ._. Patients_NNS with_IN
          leukemic_JJ meningitis_NNS were_VBD excluded_VBN ._. All_DT patients_NNS gave_VBD
          signed_VBN informed_VBN consent_NN and_CC were_VBD treated_VBN on_IN clinical_JJ
          protocols_NNS approved_VBN by_IN the_DT Cleveland_NNP Clinic_NNP Foundation_NNP 's_POS
          Institutional_NNP Review_NNP Board_NNP ._.
        
        
          EMA-G_NNP Regimen_NNP
          The_DT EMA_NNP regimen_NN contains_VBZ etoposide_NN ,_, mitoxantrone_NN and_CC
          cytarabine_NN administered_VBN in_IN a_DT timed-sequential_JJ fashion_NN ._. [_NN
          32_CD ]_NN We_PRP added_VBD G-CSF_NNP to_TO the_DT EMA_NNP regimen_NN ,_, thus_RB EMA-G_NNP ._. EMA-G_NNP
          consists_VBZ of_IN mitoxantrone_NN 12_CD mg_NN /_NN m_NN 2_CD per_IN day_NN intravenous_JJ
          (_( IV_NNP )_) bolus_JJ for_IN 3_CD days_NNS (_( day_NN 1_CD to_TO 3_LS )_) with_IN cytarabine_NN 500_CD
          mg_NN /_NN m_NN 2_CD per_IN day_NN IV_NNP continuous_JJ infusion_NN (_( CI_NNP )_) for_IN 72_CD hours_NNS
          (_( day_NN 1_CD to_TO 3_LS )_) ._. Etoposide_NNP 200_CD mg_NN /_NN m_NN 2_CD per_IN day_NN IVCI_NNP for_IN 72_CD
          hours_NNS and_CC cytarabine_NN 500_CD mg_NN /_NN m_NN 2_CD per_IN day_NN IVCI_NNP for_IN 72_CD hours_NNS
          were_VBD administered_VBN on_IN day_NN 8_CD to_TO 10_CD ._. G-CSF_NNP 5_CD mg_NN /_NN kg_NN per_IN day_NN
          subcutaneouly_RB was_VBD started_VBN on_IN day_NN 4_CD and_CC continued_VBD until_IN
          the_DT absolute_JJ neutrophil_NN count_NN (_( ANC_NNP )_) rose_VBD above_IN 0_CD ._. 5_CD Ã—_NN 10_CD
          9_CD /_NN L_NNP for_IN two_CD consecutive_JJ days_NNS (_( Fig_NNP ._. 1_LS )_) ._. Only_RB one_CD course_NN of_IN
          EMA-G_NNP induction_NN was_VBD given_VBN ._. Post_NNP remission_NN therapy_NN
          included_VBD chemotherapy_NN ,_, allogeneic_JJ bone_NN marrow_NN
          transplantation_NN (_( BMT_NNP )_) or_CC peripheral_JJ stem_NN cell_NN
          transplantation_NN (_( PSCT_NNP )_) at_IN the_DT treating_VBG physician_NN 's_POS
          discretion_NN and_CC availability_NN of_IN a_DT transplant_NN donor_NN ._.
          All_DT patients_NNS were_VBD cared_VBN for_IN in_IN semi-private_JJ rooms_NNS
          supplied_VBN with_IN HEPA_NNP filters_NNS on_IN a_DT regular_JJ oncology_NN unit_NN ._.
          All_DT patients_NNS received_VBD standard_JJ supportive_JJ care_NN including_VBG
          blood_NN component_NN support_NN for_IN severe_JJ cytopenias_NNS as_RB
          previously_RB described_VBD ._. [_NN 31_CD ]_NN Acyclovir_NNP 250_CD mg_NN /_NN m_NN 2_CD per_IN day_NN
          IV_NNP or_CC 400_CD -_: 800_CD mg_NN PO_NNP bid_NN ,_, allopurinol_NN 300_CD mg_NN PO_NNP qd_NN and_CC
          fluconazole_NN 400_CD mg_NN PO_NNP qd_NN were_VBD administered_VBN
          prophylactically_RB ._.
        
        
          Evaluation_NNP of_IN Therapy_NNP
          Bone_NNP marrow_NN aspirates_NNS and_CC biopsies_NNS were_VBD obtained_VBN on_IN
          day_NN 8_CD of_IN chemotherapy_NN and_CC then_RB at_IN the_DT discretion_NN of_IN the_DT
          treating_VBG physicians_NNS ._. When_WRB a_DT bone_NN marrow_NN aspirate_NN or_CC
          biopsy_NN obtained_VBN on_IN or_CC after_IN Day_NNP 14_CD contained_VBD 5_CD %_NN or_CC more_JJR
          blast_NN cells_NNS ,_, G-CSF_NNP was_VBD stopped_VBN ._.
          Complete_JJ remission_NN (_( CR_NNP )_) was_VBD achieved_VBN when_WRB the_DT
          following_VBG parameters_NNS were_VBD met_VBN :_: 1_LS )_) bone_NN marrow_NN was_VBD
          normocellular_NN ,_, containing_VBG <_NN 5_CD %_NN blasts_NNS ,_, >_NN 15_CD %_NN
          erythroid_NN cells_NNS ,_, and_CC >_NN 25_CD %_NN normal_JJ granulocytes_NNS ;_: 2_LS )_)
          peripheral_JJ blood_NN had_VBD neutrophils_NNS >_NN 1_CD ._. 5_CD Ã—_NN 10_CD 9_CD /_NN L_NNP ,_,
          hemoglobin_NN >_NN 11_CD gm_NN /_NN dl_NN ,_, and_CC platelets_NNS >_NN 1_CD Ã—_NN 10_CD 11_CD /_NN L_NNP ;_:
          3_LS )_) no_DT evidence_NN of_IN extramedullary_JJ leukemia_NN ,_, and_CC 4_LS )_) all_DT of_IN
          the_DT above_JJ fulfilled_VBN for_IN at_IN least_JJS 4_CD weeks_NNS ._. Nonresponse_NNP to_TO
          EMA-G_NNP induction_NN was_VBD defined_VBN as_IN the_DT absence_NN of_IN CR_NNP after_IN
          one_CD course_NN of_IN induction_NN therapy_NN ._. Relapse_NNP was_VBD defined_VBN by_IN
          the_DT appearance_NN of_IN circulating_VBG blasts_NNS or_CC bone_NN marrow_NN
          blasts_NNS >_NN 5_CD %_NN in_IN a_DT patient_NN previously_RB in_IN complete_JJ
          remission_NN ._.
        
        
          Evaluation_NNP of_IN Toxicity_NNP
          Severity_NNP of_IN treatment-related_JJ toxicity_NN was_VBD graded_JJ
          according_VBG to_TO the_DT WHO_WP criteria_NNS (_( World_NNP Health_NNP Organization_NNP
          Handbook_NNP for_IN Reporting_NNP Results_NNS of_IN Cancer_NNP Treatment_NNP ,_,
          1979_CD ._. )_)
        
        
          Statistical_NNP Analysis_NNP
          The_DT method_NN of_IN Kaplan_NNP and_CC Meier_NNP was_VBD used_VBN to_TO analyze_VB
          overall_JJ survival_NN ,_, relapse-free_JJ survival_NN ,_, time_NN to_TO
          neutrophil_NN recovery_NN and_CC time_NN to_TO platelet_NN recovery_NN ._. Exact_JJ
          95_CD %_NN confidence_NN intervals_NNS (_( CI_NNP )_) based_VBN on_IN the_DT binomial_NN
          distribution_NN were_VBD calculated_VBN for_IN proportions_NNS such_JJ as_IN the_DT
          complete_JJ response_NN rate_NN ._.
        
      
      
        Results_NNS
        
          Patients_NNS
          From_IN August_NNP 1994_CD to_TO November_NNP 1996_CD ,_, 30_CD patients_NNS were_VBD
          enrolled_VBN onto_IN this_DT study_NN ._. One_CD patient_NN received_VBD high-dose_JJ
          cytarabine_NN instead_RB of_IN EMA-G_NNP for_IN induction_NN therapy_NN after_IN
          enrollment_NN and_CC was_VBD therefore_RB excluded_VBN from_IN further_JJ
          analysis_NN ._. Thus_RB ,_, 29_CD patients_NNS received_VBD EMA-G_NNP induction_NN
          therapy_NN and_CC are_VBP evaluable_JJ for_IN treatment-related_JJ toxicity_NN ._.
          Only_RB 28_CD patients_NNS are_VBP evaluable_JJ for_IN induction_NN response_NN
          since_IN 1_CD patient_NN was_VBD lost_VBN to_TO follow-up_JJ shortly_RB after_IN
          receiving_VBG induction_NN therapy_NN (_( no_DT evidence_NN of_IN persisting_VBG
          leukemia_NN by_IN the_DT post-induction_JJ bone_NN marrow_NN biopsy_NN )_) ._. The_DT
          characteristics_NNS of_IN the_DT evaluable_JJ patients_NNS are_VBP listed_VBN in_IN
          Table_NNP 1_CD ._. Twenty-eight_NNP patients_NNS had_VBD cytogenetic_JJ studies_NNS of_IN
          bone_NN marrow_NN aspirates_NNS ._. Most_JJS patients_NNS (_( 61_CD %_NN )_) had_VBD
          unfavorable_JJ karyotypes_NNS ._. The_DT majority_NN of_IN patients_NNS (_( 69_CD %_NN )_)
          had_VBD secondary_JJ AML_NNP transformed_VBD from_IN either_DT MDS_NNP (_( n_NN =_SYM 10_CD )_) ,_,
          CML_NNP (_( n_NN =_SYM 5_LS )_) or_CC other_JJ myeloproliferative_JJ diseases_NNS (_( n_NN =_SYM 4_LS )_) ,_,
          or_CC secondary_JJ to_TO cytotoxic_JJ agents_NNS (_( n_NN =_SYM 1_LS )_) ._. Overall_RB ,_, 15_CD
          patients_NNS with_IN secondary_JJ ,_, but_CC untreated_JJ ,_, AML_NNP were_VBD
          enrolled_VBN ._. Four_CD patients_NNS were_VBD enrolled_VBN with_IN AML_NNP refractory_JJ
          to_TO previous_JJ induction_NN therapy_NN ,_, and_CC 10_CD were_VBD enrolled_VBN with_IN
          relapsed_JJ AML_NNP ._.
        
        
          Recovery_NNP of_IN neutrophil_NN and_CC platelet_NN counts_NNS
          The_DT median_JJ time_NN from_IN the_DT start_NN of_IN chemotherapy_NN to_TO
          recovery_NN of_IN an_DT absolute_JJ neutrophil_NN count_NN exceeding_VBG 0_CD ._. 5_CD Ã—_NN
          10_CD 9_CD /_NN L_NNP was_VBD 30_CD days_NNS (_( range_NN ,_, 19_CD to_TO 47_CD days_NNS )_) ._. Three_CD patients_NNS
          died_VBD of_IN febrile_NN neutropenia_NN and_CC sepsis_NN during_IN induction_NN
          therapy_NN ._. The_DT median_JJ duration_NN of_IN platelet_NN transfusion_NN
          dependence_NN was_VBD 30_CD days_NNS (_( range_NN ,_, 22_CD to_TO 48_CD days_NNS )_) ._.
        
        
          Efficacy_NNP of_IN Therapy_NNP
          Twenty-eight_NNP patients_NNS are_VBP evaluable_JJ for_IN treatment_NN
          response_NN ._. Thirteen_CD patients_NNS (_( 46_CD %_NN ,_, 95_CD %_NN CI_NNP 27_CD %_NN -_: 66_CD %_NN )_)
          achieved_VBD a_DT complete_JJ remission_NN ._. Seven_CD of_IN those_DT 13_CD patients_NNS
          with_IN CR_NNP had_VBD secondary_JJ leukemia_NN ._. Twelve_CD patients_NNS (_( 43_CD %_NN )_)
          failed_VBD to_TO achieve_VB CR_NNP following_VBG induction_NN treatment_NN ._. One_CD
          of_IN the_DT non-responders_JJ had_VBD no_DT evidence_NN of_IN leukemia_NN after_IN
          induction_NN treatment_NN and_CC proceeded_VBD to_TO bone_NN marrow_NN
          transplant_NN before_IN meeting_VBG all_DT of_IN the_DT criteria_NNS for_IN
          complete_JJ remission_NN ._. Three_CD patients_NNS (_( 10_CD %_NN )_) died_VBD during_IN
          induction_NN treatment_NN ._.
          Of_IN the_DT 13_CD patients_NNS who_WP achieved_VBD CR_NNP ,_, 6_CD patients_NNS
          received_VBD further_JJ consolidation_NN chemotherapy_NN (_( 3_CD with_IN high_JJ
          dose_NN cytarabine_NN ,_, and_CC 3_CD with_IN intermediate_JJ dose_NN cytarabine_NN
          combined_VBN with_IN daunorubicin_NN ,_, etoposide_NN ,_, or_CC interleukin-_NN 2_LS )_) ,_,
          and_CC 6_CD patients_NNS received_VBD either_CC allogeneic_JJ BMT_NNP or_CC
          allogeneic_JJ PSCT_NNP ._. One_CD patient_NN relapsed_JJ before_IN any_DT
          post-remission_JJ therapy_NN was_VBD given_VBN ._. Of_IN the_DT 13_CD patients_NNS who_WP
          did_VBD not_RB achieve_VB CR_NNP ,_, 1_CD received_VBD salvage_VB chemotherapy_NN ,_, 2_CD
          received_VBD allogeneic_JJ BMT_NNP ,_, and_CC 10_CD died_VBD due_JJ to_TO rapid_JJ disease_NN
          progression_NN ._.
        
        
          Survival_NNP
          The_DT median_JJ overall_JJ survival_NN (_( OS_NNP )_) for_IN all_DT evaluable_JJ
          patients_NNS is_VBZ 9_CD months_NNS (_( range_NN ,_, 0_CD ._. 5_CD -_: 66_CD months_NNS )_) ._. Median_JJ
          relapse_NN free_JJ survival_NN (_( RFS_NNP )_) for_IN those_DT who_WP achieved_VBD CR_NNP is_VBZ
          3_CD months_NNS (_( range_NN ,_, 0_CD ._. 5_CD -_: 63_CD months_NNS )_) with_IN 6_CD patients_NNS censored_VBN
          at_IN allogeneic_JJ BMT_NNP or_CC PSCT_NNP ._. At_IN five-years_JJ of_IN follow-up_JJ ,_, 3_CD
          patients_NNS (_( 11_CD %_NN )_) were_VBD still_RB alive_JJ ._. Two_CD of_IN them_PRP were_VBD in_IN CR_NNP ,_,
          one_CD of_IN whom_WP had_VBD allogeneic_JJ BMT_NNP and_CC the_DT other_JJ had_VBD high_JJ
          dose_NN cytarabine_NN as_IN post-remission_JJ therapy_NN ._. The_DT third_JJ
          patient_NN is_VBZ alive_JJ with_IN recurrent_JJ leukemia_NN ._.
        
        
          Treatment-related_NNP Toxicity_NNP
          All_DT patients_NNS experienced_VBD fever_NN in_IN the_DT setting_NN of_IN
          severe_JJ neutropenia_NN ._. Fifteen_CD (_( 15_CD %_NN )_) patients_NNS had_VBD documented_VBN
          infections_NNS ._. Three_CD patients_NNS (_( 10_CD %_NN )_) died_VBD from_IN febrile_NN
          neutropenia_NN and_CC sepsis_NN ._. Other_JJ WHO_WP grades_NNS III-IV_NNP toxicity_NN
          included_VBD mucositis_NNS (_( 17_CD %_NN )_) ,_, diarrhea_NN (_( 17_CD %_NN )_) ,_, skin_NN rash_NN
          (_( 14_CD %_NN )_) ,_, nausea_NN and_CC vomiting_NN (_( 14_CD %_NN )_) ,_, bleeding_VBG (_( 3_CD %_NN )_) ._. Ten_CD
          (_( 34_CD %_NN )_) patients_NNS had_VBD reversible_JJ hyperbilirubinemia_NN and_CC 5_CD
          (_( 17_CD %_NN )_) had_VBD WHO_WP grades_NNS III-IV_NNP renal_JJ insufficiency_NN ._. Three_CD
          (_( 10_CD %_NN )_) patients_NNS experienced_VBD severe_JJ neurological_JJ toxicity_NN
          (_( 1_CD with_IN seizure_NN ,_, 2_CD with_IN severe_JJ vertigo_NN )_) but_CC those_DT
          complications_NNS resolved_VBN shortly_RB after_IN the_DT completion_NN of_IN
          induction_NN therapy_NN ._. GCSF_NNP was_VBD stopped_VBN in_IN 1_CD patient_NN due_JJ to_TO
          persisting_VBG peripheral_JJ blasts_NNS ._. When_WRB G-CSF_NNP was_VBD discontinued_VBN
          the_DT peripheral_JJ blasts_NNS cleared_VBD and_CC the_DT patient_NN achieved_VBD a_DT
          complete_JJ remission_NN ._.
        
      
      
        Discussion_NNP
        Hematopoietic_NNP growth_NN factors_NNS clearly_RB increase_VBP the_DT
        cytotoxicity_NN of_IN cytarabine_NN to_TO leukemia_NN cells_NNS 
        in_IN vitro_NN ._. [_NN 33_CD ]_NN Clinically_NNP ,_,
        however_RB ,_, they_PRP fail_VBP to_TO increase_VB remission_NN rates_NNS when_WRB started_VBD
        from_IN 24_CD to_TO 48_CD hours_NNS before_IN any_DT chemotherapy_NN ._. [_NN 20_CD 21_CD 22_CD 23_CD
        ]_NN Potential_JJ explanations_NNS for_IN the_DT failure_NN of_IN growth_NN factors_NNS
        to_TO improve_VB results_NNS when_WRB administered_VBN in_IN this_DT fashion_NN may_MD
        reflect_VB either_CC their_PRP$ adverse_JJ effect_NN on_IN a_DT large_JJ leukemic_JJ
        burden_NN or_CC the_DT necessary_JJ delay_NN to_TO the_DT onset_NN of_IN chemotherapy_NN ._.
        [_NN 34_CD ]_NN In_IN our_PRP$ study_NN we_PRP started_VBD growth_NN factors_NNS after_IN the_DT
        initial_JJ leukemic_JJ burden_NN was_VBD reduced_VBN and_CC then_RB optimized_JJ the_DT
        timing_NN of_IN a_DT second_JJ course_NN of_IN chemotherapy_NN to_TO take_VB advantage_NN
        of_IN known_VBN leukemic_JJ blast_NN cell-cycle_JJ kinetics_NNS ._. [_NN 27_CD ]_NN Our_PRP$
        results_NNS are_VBP comparable_JJ to_TO those_DT achieved_VBN with_IN other_JJ salvage_NN
        chemotherapeutic_JJ regimens_NNS that_WDT employ_VBP high-dose_JJ cytarabine_NN ._.
        [_NN 35_CD 36_CD 37_CD 38_CD 39_CD ]_NN
        Rather_RB than_IN use_NN a_DT standard_JJ high-dose_JJ cytarabine_NN regimen_NN
        we_PRP employed_VBN the_DT EMA_NNP chemotherapy_NN protocol_NN devised_VBN by_IN
        Archimbaud_NNP and_CC colleagues_NNS ._. [_NN 40_CD ]_NN This_DT regimen_NN is_VBZ effective_JJ
        in_IN patients_NNS with_IN relapsed_JJ and_CC refractory_JJ AML_NNP with_IN a_DT
        reported_VBN CR_NNP rate_NN of_IN 60_CD %_NN ._. In_IN addition_NN EMA_NNP avoids_VBZ the_DT
        cerebellar_NN neurotoxicity_NN of_IN high-dose_JJ cytarabine_NN ._.
        Recognizing_NNP the_DT potential_JJ value_NN of_IN hematopoietic_JJ growth_NN
        factors_NNS ,_, Archimbaud_NNP and_CC colleagues_NNS added_VBD GM-CSF_NNP to_TO the_DT EMA_NNP
        regimen_NN beginning_VBG on_IN Day_NNP 4_CD of_IN treatment_NN ._. Unlike_IN the_DT current_JJ
        report_NN ,_, however_RB ,_, GM-CSF_NNP was_VBD discontinued_VBN on_IN Day_NNP 10_CD of_IN
        treatment_NN ._. Unfortunately_RB the_DT addition_NN of_IN GM-CSF_NNP did_VBD not_RB
        increase_VB the_DT CR_NNP rate_NN when_WRB it_PRP was_VBD compared_VBN to_TO placebo_NN in_IN a_DT
        prospective_JJ randomized_JJ study_NN in_IN patients_NNS with_IN relapsed_JJ and_CC
        refractory_JJ AML_NNP ._. [_NN 41_CD ]_NN The_DT results_NNS with_IN EMA_NNP and_CC EMA_NNP plus_CC
        GM-CSF_NNP are_VBP compared_VBN with_IN our_PRP$ own_JJ results_NNS in_IN Table_NNP 2_CD ._.
        Clearly_RB the_DT patient_NN population_NN in_IN our_PRP$ study_NN was_VBD
        different_JJ than_IN the_DT population_NN studied_VBN in_IN the_DT other_JJ two_CD
        studies_NNS employing_VBG the_DT EMA_NNP regimen_NN ._. Our_PRP$ population_NN is_VBZ older_JJR
        and_CC a_DT majority_NN of_IN our_PRP$ patients_NNS had_VBD secondary_JJ AML_NNP ._. These_DT two_CD
        characteristics_NNS are_VBP among_IN the_DT most_RBS predictive_JJ of_IN a_DT poor_JJ
        outcome_NN ._. Although_IN 15_CD of_IN our_PRP$ patients_NNS were_VBD untreated_JJ at_IN the_DT
        time_NN of_IN study_NN enrollment_NN all_DT 15_CD had_VBD secondary_JJ AML_NNP and_CC 5_CD of_IN
        them_PRP had_VBD CML_NNP in_IN blast_NN crisis_NN unresponsive_JJ to_TO hydroxyurea_NN
        therapy_NN ._. The_DT poor-risk_JJ features_NNS of_IN our_PRP$ patient_NN population_NN
        probably_RB explain_VB our_PRP$ relatively_RB low_JJ CR_NNP rate_NN compared_VBN to_TO
        other_JJ EMA_NNP studies_NNS but_CC also_RB confirm_VB the_DT efficacy_NN of_IN our_PRP$
        treatment_NN protocol_NN since_IN remissions_NNS would_MD only_RB be_VB expected_VBN
        in_IN 40_CD -_: 50_CD %_NN of_IN untreated_JJ patients_NNS with_IN secondary_JJ AML_NNP
        receiving_VBG initial_JJ induction_NN chemotherapy_NN ._. [_NN 42_CD 43_CD 44_CD ]_NN
        Our_PRP$ study_NN did_VBD not_RB demonstrate_VB a_DT significant_JJ advantage_NN to_TO
        the_DT addition_NN of_IN G-CSF_NNP to_TO the_DT EMA_NNP regimen_NN ._. Potential_JJ reasons_NNS
        include_VBP the_DT possibility_NN that_IN G-CSF_NNP failed_VBD to_TO increase_VB the_DT
        population_NN of_IN leukemic_JJ stem_NN cells_NNS in_IN S-_NNP phase_NN over_IN that_DT
        achieved_VBD with_IN chemotherapy_NN alone_RB ._. Alternatively_RB recruitment_NN
        of_IN blasts_NNS into_IN S-_NNP phase_NN may_MD not_RB increase_VB cytotoxicity_NN to_TO a_DT
        clinically_RB significant_JJ degree_NN ._. Finally_RB even_RB if_IN S-_NNP phase_NN
        increases_NNS cytotoxicity_NN and_CC G-CSF_NNP is_VBZ effective_JJ in_IN increasing_VBG
        the_DT proportion_NN of_IN blasts_NNS in_IN S-_NNP phase_NN these_DT effects_NNS may_MD not_RB
        be_VB sufficient_JJ for_IN patients_NNS with_IN advanced_JJ leukemia_NN ._. In_IN the_DT
        few_JJ studies_NNS exploring_VBG the_DT role_NN of_IN timed-sequential_JJ
        chemotherapy_NN as_IN primary_JJ treatment_NN for_IN 
        de_IN novo_NN untreated_JJ AML_NNP results_NNS have_VBP
        been_VBN more_JJR encouraging_VBG with_IN high_JJ remission_NN rates_NNS and_CC
        prolonged_JJ survival_NN ._. [_NN 45_CD 46_CD ]_NN
        An_DT initial_JJ concern_NN with_IN EMA-G_NNP was_VBD the_DT effect_NN the_DT
        concurrent_JJ administration_NN of_IN G-CSF_NNP and_CC chemotherapy_NN might_MD
        have_VB on_IN bone_NN marrow_NN recovery_NN ._. However_RB ,_, the_DT concern_NN was_VBD
        unfounded_JJ since_IN the_DT median_JJ time_NN to_TO neutrophil_NN and_CC platelet_NN
        recovery_NN is_VBZ not_RB different_JJ than_IN that_DT noted_VBD with_IN EMA_NNP (_( Table_NNP
        2_LS )_) ._. This_DT observation_NN suggests_VBZ that_IN G-CSF_NNP may_MD be_VB
        administered_VBN concurrently_RB with_IN chemotherapy_NN without_IN an_DT
        increase_NN in_IN toxicity_NN to_TO normal_JJ residual_JJ bone_NN marrow_NN ._. Other_JJ
        studies_NNS utilizing_VBG hematopoietic_JJ growth_NN factors_NNS administered_VBN
        before_IN and_CC concurrently_RB with_IN chemotherapy_NN also_RB demonstrate_VB
        no_DT adverse_JJ effect_NN on_IN bone_NN marrow_NN recovery_NN ._. [_NN 20_CD 21_CD 22_CD ]_NN
      
      
        Conclusions_NNP
        The_DT treatment_NN of_IN advanced_VBD high-risk_JJ AML_NNP patients_NNS remains_VBZ
        challenging_VBG ._. The_DT use_NN of_IN EMA-G_NNP in_IN the_DT current_JJ study_NN failed_VBD
        to_TO demonstrate_VB a_DT better_JJR CR_NNP rate_NN than_IN published_VBN data_NNS of_IN EMA_NNP
        alone_RB or_CC EMA_NNP with_IN GM-CSF_NNP (_( EMA-GM_NNP )_) ._. However_RB ,_, the_DT 46_CD %_NN CR_NNP rate_NN
        achieved_VBN in_IN our_PRP$ cohort_NN of_IN patients_NNS with_IN a_DT higher_JJR proportion_NN
        of_IN secondary_JJ AML_NNP and_CC older_JJR median_JJ age_NN suggests_VBZ that_IN the_DT
        EMA-G_NNP regimen_NN deserves_VBZ further_JJ study_NN in_IN a_DT population_NN of_IN
        patients_NNS with_IN less_JJR advanced_VBD disease_NN ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD
      
      
        Author_NN 's_POS Contributions_NNP
        X-YH_NNP collected_VBD and_CC compiled_VBN the_DT data_NNS and_CC reviewed_VBD the_DT
        manuscript_NN with_IN MK_NNP ._. PE_NNP participated_VBD in_IN the_DT design_NN of_IN the_DT
        study_NN ,_, performed_VBD the_DT statistical_JJ analysis_NN and_CC wrote_VBD the_DT
        statistical_JJ section_NN ._. MH_NNP ,_, AL_NNP ,_, BP_NNP ,_, and_CC SA_NNP conducted_VBD the_DT
        study_NN ,_, contributed_VBD patients_NNS ,_, and_CC commented_VBD on_IN the_DT data_NNS
        analysis_NN and_CC manuscript_NN ._. MK_NNP conceived_VBD of_IN the_DT study_NN ,_,
        reviewed_VBD the_DT data_NNS collection_NN and_CC analytical_JJ processes_NNS ,_, and_CC
        wrote_VBD the_DT body_NN of_IN the_DT manuscript_NN ._. All_DT authors_NNS read_VBP and_CC
        approved_VBD the_DT final_JJ manuscript_NN ._.
      
      
        Abbreviations_NNP
        AML_NNP ,_, acute_JJ myelogenous_JJ leukemia_NN ._. G-CSF_NNP ,_, granulocyte_NN
        colony-stimulating_JJ Factor_NN ._. GM-CSF_NNP ,_, granulocyte-macrophage_JJ
        colony-stimulating_JJ Factor_NN ._. EMA_NNP ,_, etoposide_NN ,_, mitoxantrone_NN and_CC
        cytarabine_NN ._. EMA-G_NNP ,_, EMA_NNP and_CC G-CSF_NNP ._.
      
    
  
